v19n52 pct 2ndonlineservices.ipophil.gov.ph/.../v19n52_pct_2nd.pdf · 2016. 5. 13. · ushioda[jp]:...

Intellectual Property Center, 28 Upper McKinley Rd. McKinley Hill Town Center, Fort Bonifacio, Taguig City 1634 Philippines

Tel. No. 238-6300 Website: http://www.ipophil.gov.ph e-mail: [email protected]

Volume 19 Number 52 Date Released: May 13, 2016

Invention Granted Under R.A. 8293 (PCT)

1 INVENTIONS

[19] INTELLECTUAL PROPERTY PHILIPPINES

[12] INVENTION GRANT

[21] Registration Number: 1/2007/500772 Document Code: B1

[45] Issue Date: 1 March 2016

[22] Date Filed: 11 April 2007

[54] Title: PHARMACEUTICAL COMPOSITIONS COMPRISING LEVETIRACETAM AND PROCESS FOR THEIR PREPARATION

[71] Proprietors(s): GLAXOSMITHKLINE TRADING SERVICES LIMITED [IE]

[72] Inventor(s): MICHEL DELEERS[BE]: JEAN-BENOÎT HUBERT[BE]

[73] Assignee(s): GLAXOSMITHKLINE TRADING SERVICES LIMITED [IE]

[74] Attorney / Agent: E. B. ASTUDILLO & ASSOCIATES

[30] Priority Data: 05016189.2 26/07/2005 EP and 05016945.7 04/08/2005 EP

[51] International Class 8: A 61K 31/4015, 9/20, 9/36, A 61P 25/08

[57] Abstract:

The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation.

Representative Drawing(s):




[56] Reference(s) Cited and/or Considered:

Category Document description Relevant to claim No.

Document No.

ROTE LISTE SERVICE GMBH: "Rote Liste 2003"; ECV Editio Cantor, Aulendorf; 2002

1-36 1

US 2004/092575 A1; Peuvot et al,; May 13, 2004

1-36 2

WO 2004/105682 A2; Kikuchi et al.; December 9, 2004

1-36 3

No. of Claims: 36








[22] Date Filed: 29 May 2008

[54] Title: EQUAL-CONTAINING FERMENTATION PRODUCT OF SOYBEAN EMBRYONIC AXIS, AND METHOD FOR PRODUCTION THEREOF

[71] Proprietors(s): OTSUKA PHARMACEUTICAL CO., LTD. [JP]

[72] Inventor(s): HIROYUKI KIMURA[JP]: TAKESHI YAMAUCHI[JP]: TOMOMI UENO[JP]: TOSHIMI SUZUKI[JP]: KENTARO TADANO[JP]: IKUTARO SATO[JP]: SHIGETO UCHIYAMA[JP]: MASAHIRO OONO[JP]: MASATOSHI MIZUNO[JP]

[73] Assignee(s): OTSUKA PHARMACEUTICAL CO., LTD. [JP]

[74] Attorney / Agent: FEDERIS AND ASSOCIATES LAW OFFICES

[30] Priority Data: 2005-352337 06/12/2005 JP

[51] International Class 8: A 23L 1/20, 1/30, A 61K 35/74, A 61P 13/08, 15/12, 19/10, 3/00

[57] Abstract:

An object of the invention is to provide an equol- containing fermented soybean hypocotyl material that is useful for foods, pharmaceutical preparations, cosmetic products, etc. The equal- containing fermented soybean hypocotyl material of the invention is obtained by fermenting soybean hypocotyls using at least one microorganism having an equol- producing ability by utilizing at least one daidzein compound selected from the group consisting of diadzein glycosides, daidzein and dihydrodaidzein.



NONE

No. of Claims: 17








[22] Date Filed: 17 October 2008

[54] Title: ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR OMEGA

[71] Proprietors(s): NIPPON CHEMIPHAR CO., LTD. [JP]

[72] Inventor(s): SHOGO SAKUMA[JP]: NOBUTAKA MOCHIDUKI[JP]: MASATOSHI USHIODA[JP]: RIE TAKAHASHI[JP]: TOMIO YAMAKAWA[JP]: SEIICHIRO MASUI[JP]

[73] Assignee(s): NIPPON CHEMIPHAR CO., LTD. [JP]

[74] Attorney / Agent: ORTEGA DEL CASTILLO BACORRO ODULIO CALMA AND CARBONELL

[30] Priority Data: 2006-114561 18/04/2006 JP

[51] International Class 8: A 61K 31/381, 31/421, 31/426, A 61P 1/04, 1/12, 1/16, 1/18, 11/06, 17/00, 17/06, 17/10, 17/14, 3/06, 3/10, 7/02, 9/00, 9/04, 9/10, 9/12, C 07D 263/32

[57] Abstract:

A compound represented by the general formula (II) below or a salt thereof is used as an activating agent for PPARδ

where Ga represents O, CH2 or the like; Aa represents a thiazole, oxazole or thiophene which may have a substituent such as C1-8 alkyl, C1-8 alkoxy, halogen, C1-8 alkyl substituted with halogen or the like; Ba is a C1-8 alkylene or C2-8 alkenylene chain; and each of R1a and R2a independently is hydrogen, C1-8 alkyl, C1-8 alkoxy, halogen, C1-8alkyl substituted with halogen or the like.

Representative Drawing(s): NONE


NONE

No. of Claims: 12








[22] Date Filed: 14 November 2008

[54] Title: ETHYL 3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)PHENYLAMINO]-METHYL}-1-METHYL-1H-BENZIMIDAZOLE-5-CARBONYL)-PYRIDIN-2-YL-AMINO]PROPIONATE METHANESULPHONATE

[71] Proprietors(s): BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE]

[72] Inventor(s): ULRICH BRAUNS[DE]: NORBERT HAUEL[DE]: PETER SIEGER[DE]

[73] Assignee(s): BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE]

[74] Attorney / Agent: CASTILLO LAMAN TAN PANTALEON & SAN JOSE LAW OFFICES

[30] Priority Data: 102 09 985.5 07/03/2002 DE and 102 45 624.0 30/09/2002 DE

[51] International Class 8: C 07D 401/12

[57] Abstract:

The invention relates to a novel, orally administered form of presentation for the agent 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the pharmaceutically compatible salts thereof.




Document No.

WO 98/37075A 27 August 1998

1

No. of Claims: 1







[45] Issue Date: 17 June 2015

[22] Date Filed: 2 March 2009

[54] Title: COMPOSITE CLOSURE WITH OUTER GRIPPING LAYER

[71] Proprietors(s): CLOSURE SYSTEMS INTERNATIONAL, INC., [US]

[72] Inventor(s): DAVID BABCOCK[US]

[73] Assignee(s): CLOSURE SYSTEMS INTERNATIONAL, INC., [US]

[74] Attorney / Agent: ROMULO MABANTA BUENAVENTURA SAYOC AND DELOS ANGELES

[30] Priority Data: 11/516123 06/09/2006 US

[51] International Class 8: B 65D 41/00, 41/04

[57] Abstract:

A composite closure for an associated container is configured to facilitate gripping and manipulation by consumers, as well as handling of closures by automated equipment. The closure includes an inner closure cap, and an outer gripping layer which is applied to at least the periphery of a skirt portion of the closure cap. Notably, the closure cap includes at least one outwardly projecting element which projects to at least the surface of the outer gripping layer. In one aspect of the invention, a plurality of projecting elements are provided in the form of annular elements which project beyond the surface of the outer gripping layer along respective margins thereof, thus facilitating handling by automated equipment. In another aspect of the invention, the projecting portion comprises graphical elements which extend through the outer gripping layer for enhanced gripping and visual appeal.






Category Document description

Relevant to claim No.

Document No.

US2394135 M. BAAR ALL 1

US5840135 GRANT et. al.

ALL 2

US5443172 J. GABRIELE

ALL 3

No. of Claims: 4









[54] Title: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER

[71] Proprietors(s): ONCOMED PHARMACEUTICALS, INC. [US]

[72] Inventor(s): GURNEY, AUSTIN [US]: HOEY, TIMOHTY [US]: SATYAL, SANJEEV [US]: AXELROD, FUMIKO [US]

[73] Assignee(s): ONCOMED PHARMACEUTICALS, INC. [US]

[74] Attorney / Agent: E.B. ASTUDILLO AND ASSOCIATES

[30] Priority Data: 60/847,904 29/09/2006 US; 60/886,260 23/01/2007 US and 60/942,542 07/06/2007 US

[51] International Class 8: C 07H 21/04, C 07K 16/00, C 12N 15/00, C 12P 21/08

[57] Abstract:

An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering therapeutically effective amount of an anti-DLL4 antibody.



NONE

No. of Claims: 48









[54] Title: METASTIN DERIVATIVES AND USE THEREOF

[71] Proprietors(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED, [JP]

[72] Inventor(s): TAIJI ASAMI[JP]: NAOKI NISHIZAWA[JP]

[73] Assignee(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED, [JP]


[30] Priority Data: 2006-290536 25/10/2006 JP; 2007-021387 31/01/2007 JP and 2007-221911 25/08/2007 JP

[51] International Class 8: A 61K 38/16, C 07K 14/47

[57] Abstract:

The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotropic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids, the metastin derivatives of the present invention achieve more improved blood stability, solubility, etc., reduced gelation tendency, improved pharmacokinetics, as well as exhibit an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity. The metastin derivatives of the present invention also have a gonadotropic hormone secretion suppressing activity, sex hormone secretion suppressing activity, etc.



NONE

No. of Claims: 9








[22] Date Filed: 7 December 2009

[54] Title: EXTRUDATES WITH IMPROVED TASTE MASKING

[71] Proprietors(s): BAYER INTELLECTUAL PROPERTY GMBH [DE]

[72] Inventor(s): ANDREA MICHALK[DE]: CLAUDIA REITZ[CH]: HANS-JUERGEN HAMANN[DE]: PETER KLEINEBUDDE[DE]: VENKATA-RANGARAO KANIKANTI[DE]

[73] Assignee(s): BAYER INTELLECTUAL PROPERTY GMBH [DE]


[30] Priority Data: 10 2007 026 550.8 06/08/2007 DE

[51] International Class 8: A 61K 9/00, 9/14, 9/16

[57] Abstract: The invention relates to extrudates comprising one or more Pharmaceutical active substances, where the extrudates have a strand diameter of 0.5 mm or less, and to the use of these extrudates for the medicaments.



NONE

No. of Claims: 14








[22] Date Filed: 11 December 2009

[54] Title: MONOCLONAL ANTI BETA AMYLOID ANTIBODY

[71] Proprietors(s): GENENTECH, INC. [US] and AC IMMUNE S.A. [CH]

[72] Inventor(s): RYAN WATTS[US]: ANDREA PFEIFER[CH]: ANDREAS MUHS[CH]: MARIA PIHLGREN[CH]

[73] Assignee(s): GENENTECH, INC. [US] and AC IMMUNE S.A. [CH]



[51] International Class 8: A 61K 39/395, A 61P 25/28, C 07K 16/18, C 12N 5/20

[57] Abstract:

The present application is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present application provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ss-amyloid proteins. The antibodies enabled by the teaching of the present application are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).



NONE

No. of Claims: 249







[45] Issue Date: 11 February 2016

[22] Date Filed: 18 January 2010

[54] Title: DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS

[71] Proprietors(s): LIFESCAN, INC. [US]

[72] Inventor(s): ALIREZA REZANIA[US]

[73] Assignee(s): LIFESCAN, INC. [US]

[74] Attorney / Agent: ROMULO MABANTA BUENAVENTURA SAYOC AND DELOS ANGELES

[30] Priority Data: 11/779,311 18/07/2007 US

[51] International Class 8: C 12N 5/00, 5/08

[57] Abstract:

The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improve method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.



Category Document description Relevant to claim

No.

Document No.

WO 2007/051038 A (CYTHERA INC, US) 03 May 2007 (03.05.2007)

1

D`AMOUR K A ET AL: "Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells" NATURE BIOTECH, NY, US, vol. 24, no. 11, 01 January 2006 (01.01.2006) pp. 1392-1401, XP002423119

2

LIU Y ET AL: "A novel chemical-defined medium with bFGF and N2B27 supplements supports undifferentiated growth in human embryonic stem cells" BIOCHEM AND BIOPHYSICAL RES COMM, US,

3




vol. 346, no. 1, 21 July 2006 (21.07.2006), pp. 131-139, XP024925297

SEGEV H ET AL: "Differentiation of human embryonic stem cells into insulin-producing clusters" STEM CELLS, US, vol. 22, no. 3, 01 January 2004 (01.01.2004), pp. 265-274, XP009038283

4

No. of Claims: 27







[45] Issue Date: 11 February 2016


[54] Title: COMPOUNDS AND METHODS

[71] Proprietors(s): CLANOTECH AB [SE]

[72] Inventor(s): WESTMAN, Jacob[SE]: MALM, Johan[SE]: NEKHOTIAEVA, Natalia[SE]: BACKMAN, Ulrika[SE]: WANNBERG, Johan[SE]

[73] Assignee(s): CLANOTECH AB [SE]

[74] Attorney / Agent: BUCOY POBLADOR & ASSOCIATES

[30] Priority Data: 07120799.7 15/11/2007 EP and 60/988,147 15/11/2007 US

[51] International Class 8: A 61K 31/4706, 45/00, A 61P 27/02, 35/00, C 07D 215/54

[57] Abstract:

A compound of formula (I)

as well as pharmaceutically acceptable salts thereof. A pharmaceutical composition comprising a therapeutically effective amount of the compound. The compound is useful for the treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke, ischemic myocardium, atherosclerosis, macular edema or psoriasis.







No.

Document No.

US 5,650,415 A (TANG PENG CHO ET.AL.) 22 July 1997 (22.07.1997)

1

WO 00/68201 A (ASTRAZENECA AB) 16 November 2000 (16.11.2000)

2

WO 2007/139496 A (CLANOTECH AB) 06 December 2007 (06.12.2007)

3

XP003018391 (SAPELKIN V.M ET.AL.) "Search for protein kinase CK2 inhibitors among 3-carboxy-4-aminoquinoline derivative", Ukrainica Bioorganica Acta, volume 2, no. 1, pages 28-32, 2005

4

No. of Claims: 43









[54] Title: MYCOPLASMA BOVIS VACCINE

[71] Proprietors(s): BOEHRINGER INGELHEIM VETMEDICA, INC., [US]

[72] Inventor(s): MICHAEL BECK[US]: JEFFREY KNITTEL[US]

[73] Assignee(s): BOEHRINGER INGELHEIM VETMEDICA, INC., [US]

[74] Attorney / Agent: CASTILLO LAMAN TAN PANTALEON & SAN JOSE LAW OFFICES

[30] Priority Data: 60/983,482 29/10/2007 US and 61/074,552 25/06/2008 US

[51] International Class 8: A 61K 39/02

[57] Abstract:

The present invention relates to new attenuated M. bovis bacteria strains. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of an of those attenuated M. bovis bacteria strain, their manufacture and use for the treatment and prophylaxis of M. bovis infections.



NONE

No. of Claims: 23








[22] Date Filed: 7 May 2010

[54] Title: METHOD FOR PRODUCING LIPID

[71] Proprietors(s): AALTO UNIVERSITY FOUNDATION, [FI]

[72] Inventor(s): OSSI PASTINEN[FI]: SIMO LAAKSO[FI]: SANNA HOKKANEN[FI]: MIIA MUJUNEN[FI]

[73] Assignee(s): AALTO UNIVERSITY FOUNDATION, [FI]

[74] Attorney / Agent: HECHANOVA AND CO. INC.

[30] Priority Data: 20075810 14/11/2007 FI and 61/003,056 14/11/2007 US

[51] International Class 8: C 12P 19/02, 7/64

[57] Abstract:

The invention relates to a method for forming a lipid or a lipid mixture from an organic source material comprising cellulose, hemicellulose, starch, non-starch polysaccharide, any mixture thereof or degradation products thereof. According to the method, the source material is treated one or more times with water, an aqueous solution of acid or alkali, and the precipitate and the filtrate are separated. The precipitate obtained from the treatments mentioned above can be subjected to mechanical or thermo-mechanical grinding, or the precipitate can be treated with a strong acid, or the precipitate can be acidified and ground mechanically or thermo-mechanically. After the treatments, the precipitate and the filtrate are separated.; A lipid-producing microorganism is contacted with the source material or the obtained filtrate(s) in a culture medium, whereby the microorganism cells begin to produce lipid, and the lipids are recovered.






Category Document description

Relevant to claim No.

Document No.

US 4368056 A 1-19 1 US 5221357 1-19 2 WO2001/032715 A1 1-19 3

No. of Claims: 35







[45] Issue Date: 22 September 2015

[22] Date Filed: 2 June 2010

[54] Title: SEED TREATMENT FORMULATIONS AND METHODS OF USE

[71] Proprietors(s): VALENT U.S.A. CORPORATION, [US]

[72] Inventor(s): KAREN ARTHUR[US]: FRANK GONZALES[US]: MICHAEL SEITZ[US]

[73] Assignee(s): VALENT U.S.A. CORPORATION, [US]

[74] Attorney / Agent: SYCIP SALAZAR HERNANDEZ AND GATMAITAN


[51] International Class 8: A 01N 25/26

[57] Abstract:

The present invention generally relates to aqueous seed treatment formulations comprising a pesticidal agent, a polyvinyl alcohol (PVA), a graft copolymer, and a plasticizer. In one embodiment of the invention, PVA-compatible polymer emulsions are employed. The present invention also relates to uses of the disclosed compositions for protecting seeds from pests.




Document No.

WO2005/048707 A1 Kang, et al - 2 June 2005

1-29 1

WO2007/0275985 Gabauer, et al - 29 November 2007

1-29 2

No. of Claims: 32








[22] Date Filed: 8 July 2011

[54] Title: ANTI-SIGLEC-15 ANTIBODY

[71] Proprietors(s): DAIICHI SANKYO COMPANY, LTD. [JP]

[72] Inventor(s): HIRUMA, YOSHIHARU[JP]: NAKAYAMA, MAKIKO[JP]: TSUDA, EISUKE[JP]: TAKIZAWA, TAKESHI[JP]

[73] Assignee(s): DAIICHI SANKYO COMPANY, LTD. [JP]

[74] Attorney / Agent: ORTEGA, BACORRO et al.

[30] Priority Data: 2009-094613 09/04/2009 JP

[51] International Class 8: A 61K 39/395, A 61P 1/02, 19/08, 19/10, 3/14, 35/00, 35/04, C 07K 16/18, 16/46, C 12N 1/15, 1/19, 1/21, 15/09, 5/10, C 12P 21/08

[57] Abstract:

Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclasts formation, and the like.




No.

Document No.

ANGATA, T. ET AL.: "Siglec-15, an immune system siglec conserved throughout vertebrate evolution" GLYCOBIOLOGY, vol. 17, no. 8, August 2007, pp. 838-846

all 1

WO 2007/093042 A1 (ALETHIA BIOTHERAPEUTICS INC) August 23, 2007

all 2

No. of Claims: 457







[45] Issue Date: 23 October 2015


[54] Title: 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE

[71] Proprietors(s): DAIICHI SANKYO COMPANY, LIMITED [JP]

[72] Inventor(s): KURIBAYASHI, TAKESHI[JP]: KUBOTA, HIDEKI[JP]: TANAKA, NAOKI[JP]: FUKUDA, TAKESHI[JP]: TSUJI, TAKASHI[JP]: GOTO, RIKI[JP]

[73] Assignee(s): DAIICHI SANKYO COMPANY, LIMITED [JP]

[74] Attorney / Agent: ORTEGA, BACORRO, ODULIO, CALMA AND CARBONELL

[30] Priority Data: 2009-242884 21/10/2009 JP

[51] International Class 8: A 61K 31/506, A 61P 7/06, C 07D 401/06, 401/10, 401/14

[57] Abstract:

The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1):

[wherein, R1: formula (1A):

[wherein, R4 and R5: H, halogen, or alkyl; R6: H, halogen, alkyl, or the like; R7: substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group [alpha]: oxo, hydroxy, amino, or the like; ring Q1: a monocyclic heterocyclic group; ring Q2: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; ring Q3: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; X: a single bond, methylene, ethylene, or the like]; R2: alkyl, or methylsulfanyl; and R3: H, or methyl], or the like.







Document No.

WO 2008/089051 A1 (Smithkline Beecham Corp et al.) 24 July 2008

1

WO 2007/150011 A2 (Smithkline Beecham Corp et al.) 27 December 2007

2

WO 2008/089052 A2 (Smithkline Beecham Corp et al.) 24 July 2008

3

WO 2009/117269 A1 (Merck & Co. Inc. et al.) 24 September 2009

4

No. of Claims: 86







[45] Issue Date: 23 October 2015


[54] Title: POLARIZING PHOTOCHROMIC DEVICES AND METHODS OF MAKING THE SAME

[71] Proprietors(s): TRANSITIONS OPTICAL, INC. [US]

[72] Inventor(s): KUMAR, ANIL[US]: HE, MENG[US]: KELLAR II, TERRY A.[US]: BLACKBURN, FORREST R.[US]: FOLLER, PETER C. [US]: SHAO, JIPING[US]

[73] Assignee(s): TRANSITIONS OPTICAL, INC. [US]

[74] Attorney / Agent: VERALAW (DEL ROSARIO RABOCA GONZALES GRASPARIL)

[30] Priority Data: 60/484,100 01/07/2003 US

[51] International Class 8: B 29D 11/00, C 09K 9/02, G 02B 5/23, 5/30, G 02C 7/10, 7/12

[57] Abstract:

A method of making an optical element including: forming an at least partial coating of an alignment medium to at least a portion of at least one surface of a substrate and at least partially ordering at least a portion of the alignment medium; forming at least one at least partial coating of an alignment transfer material on at least a portion of the coating of the alignment medium and aligning the alignment transfer material with at least a portion of the ordered alignment medium; and forming an at least partial coating including an anisotropic material and at least one photochromic-dichroic compound on the alignment transfer material, aligning at least a portion of the anisotropic material with the at least partially aligned alignment transfer material, and aligning at least a portion of the photochromic-dichroic compound with aligned anisotropic material.







Document No.

US2007047054 (KUMAR ANIL ET. AL. 2007-03-01)

1

US2007098968 (KUMAR ANIL ET. AL. 2007-05-03)

2

US2319826 (PELLETT FRED G 1943-05-25)

3

No. of Claims: 8







[45] Issue Date: 15 June 2015


[54] Title: SOLID/FLUID SEPARATION DEVICE AND METHOD FOR TREATING BIOMASS INCLUDING SOLID/FLUID SEPARATION

[71] Proprietors(s): GREENFIELD ETHANOL INC. [CA]

[72] Inventor(s): LEHOUX, RICHARD, ROMEO[CA]: BRADT, CHRISTOPHER, BRUCE[CA]

[73] Assignee(s): GREENFIELD ETHANOL INC. [CA]


[30] Priority Data: 61/411,721 09/11/2010 US

[51] International Class 8: B 01D 25/00, 29/23, 29/46, 35/28, B 30B 3/00, 3/00, 9/12

[57] Abstract: A solid/fluid separation module and pretreatment apparatus and method enables pretreatment of biomass at high temperature and pressure with the ability to vary residence and processing times.




Document No.

US4340184 Poss July 1982

1-31 1

US3230865 Franz January 1966 1-31 2

No. of Claims: 31









[54] Title: METHODS FOR TREATING HCV

[71] Proprietors(s): ABBVIE INC. [US]

[72] Inventor(s):

BERNSTEIN, BARRY, M [US]: MENON, RAJEEV, M [US]: KHATRI, AMIT [US]: MENSING, SVEN [DE]: DUTTA, SANDEEP [US]: COHEN, DANIEL [US]: PODSADECKI, THOMAS, J [US]: BRUN, SCOTT, C [US]: AWNI, WALID, M [US]: DUMAS, EMILY, O [US]: KLEIN, CHERI, E [US]

[73] Assignee(s): ABBVIE INC. [US]

[74] Attorney / Agent: SYCIP, SALAZAR, HERNANDEZ AND GATMAITAN

[30] Priority Data: 61/550,360 21/10/2011 US; 61/562,176 21/11/2011 US; 61/587,197 17/01/2012 US; 61/600,468 17/02/2012 US; 61/619,883 03/04/2012 US; 61/656,253 06/06/2012 US and 61/711,793 10/10/2012 US

[51] International Class 8: A 61K 31/4025, 31/4178, 31/4709, 31/4725, 31/473, 31/501, 31/513, 31/5377, 45/06, A 61P 31/12, 31/14

[57] Abstract:

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1 (ABT) or therapeutic agent 2 (=ABT-333) or therapeutic agent 3 (=ABT-072) or therapeutic agent 4 (ABT), and an inhibitor of cytochrome P450 (e.g., ritonavir).




No.

Document No.

LOK ET AL: "Combination Therapy" October 2010

1-10 1

WO2010030359A2 (ENANTA PHARMACEUTICALSINC [US]; ABBOTT LAB [US]; KU YIYIN [US];MCDA) 18 March 2010

1-10 2

WO2009039127A1 (ABBOTT LAB [US]; WAGNER ROLF [US]; TUFANO MICHAEL D [US]; STEWART KENT) 26 March 2009

1-10 3

US2010317568A1 (DEGOEY 1-10 4




DAVID A [US] ETAL) 16 December 2010

No. of Claims: 10

v19n52 pct 2ndonlineservices.ipophil.gov.ph/.../v19n52_pct_2nd.pdf · 2016. 5. 13. · ushioda[jp]:...

Documents